The p53 gene is localised to chromosome arm 17pl3 (McBride et al., 1986) and codes for a 53,000 dalton nuclear protein regulating the cell cycle in a yet unclarified way (Levine, 1990; Mercer et al., 1984) . Evidence from in vitro models suggests that p53 acts as a tumour suppressor gene (Finlay et al., 1989) . Deletions of chromosome 17 alleles associated with a mutant p53 in human cancer lent further support to the tumour suppressor gene hypothesis (Knudson, 1985) . Mutations of p53 and/or allelic loss at 17p have been reported in an increasing number of different human malignancies: colon Baker et al., 1990) , breast Thompson et al., 1990; B0rresen et al., 1991) , lung Iggo et al., 1990), brain , bone (Masuda et al., 1987) , and esophagus (Hollstein et al., 1990) . The evidence accumulated so far suggests that mutant p53 may be the commonest genetic abnormality in human cancer (Harris, 1990) . Nigro et al. (1989) showed that p53 mutations cluster in four hot-spots localised in the most conserved region of the gene. Immunohistochemical studies show that antibodies raised against mutant p53 proteins and the wild-type counterpart (complexed and inactivated by the trans-dominant mutant p53 protein product) may be used as screening method for the presence of mutations (Iggo et al., 1990) . Accordingly, detectable levels of p53 protein product by immunohistochemistry suggest the existence of genetic alterations at this locus, since the very low steady-state levels of the normal protein (due to its rapid turn-over) are usually invisible by this method (Rodrigues et al., 1990 (B0rresen et al., 1991) . Sequencing of the samples with the mutations detected by CDGE was also performed using PCR for direct sequencing. PCR was performed with one biotinylated primer. The biotinylated PCR products were sequenced directly with standard dideoxy sequencing reactions using Dynabeads M280-Streptavidin (Dynal AS, Norway) as solid support (Hultman et al., 1989) . Sections from paraffin-embedded material were immunostained using a monoclonal antibody detecting both wild-type and mutant p53 (PAb 1801 -Oncogene Science). Incubation with the primary antibody was performed in dilution 1:100 (1 pig IgG, ml-') overnight. The avidin-biotin-peroxidase complex method was used (Hsu et al., 1981 (Table I) . Previous reports establishing the value of screening for mutations using both immunohistochemistry (Iggo et al., 1990) and LOH studies with pYNZ22.1 (Baker et al., 1990) , prompted us to search for mutations of p53 in the ten cases selected by these methods (immunoreactive, LOH of 17p or both). One case with LOH, non-immunoreactive, could not be further evaluated because no more DNA was available. Nine cases were further screened for mutations. Three of these nine cases showed PCR products with a mobility different from normal DNA in the CDGE (Figure 1) Our study shows that the prevalence of mutations of p53 in gastric carcinomas as assessed by immunohistochemical detection (13.3%) and by mutation (three out of nine cases studied by CDGE, i.e., 33.3%) is in the same order of magnitude as in the breast (B0rresen et al., 1991) , and in the recent report by Tamura et al. (1991) in gastric carcinomas, but lower than those reported for colon carcinomas (Scott et al., 1991) . It also shows that in gastric carcinomas, as elsewhere there seems to be a clustering of mutations (at least) in some of the p53 hot-spots. However, the presence of immunoreactivity in two cases that did not show p53 mutations may be due to mutations occurring outside the four hot-spots studied or elevated level of the normal p53 protein. Alternatively, a sampling bias due to contamination by non-neoplastic (stromal) cells and subsequent preferential PCR amplification of normal sequences might explain the observed 'false-negative' results.
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